Developing and commercializing a drug is not a static process. An asset or brand requires ongoing decision support from early Phase II through to the end of its life cycle. Biopharmaceutical companies are continuously required to make decisions based on current conditions and an uncertain future; we provide clarity on both. We focus not only on those events clients can plan for, but also predict and respond to those they cannot.